Abstract

Retrospective Study

The Outcome of Patients with Leukemia Presenting with Hyperleukocytosis Requiring Leukapheresis. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia

Khalid Ahmed Al-Anazi*, Alsaffar WA, Aljishi FK, Kanfer S, Kalogiannidis P, Alenazi W, Alshammasi Z, Albahrani A, Abduljalil O, Mutahar E, Alwakeel AM, Apostolidis I, Darweesh M, Almokhtar N, Abdulbaqi M, Albanyan O, Alshaibani Z, Raslan H and Aldayel A

Published: 15 March, 2024 | Volume 8 - Issue 1 | Pages: 008-016

Background: Patients with acute and chronic leukemia presenting with hyperleukocytosis are at risk of developing leukostasis which has serious and life-threatening complications. Leukapheresis is usually performed to reduce the complications of leukostasis in patients presenting with hyperleukocytosis and clinical manifestations compatible with leukostasis. 
Methods and materials: A retrospective study of patients with acute and chronic leukemia who received leukapheresis for hyperleukocytosis between the 1st of January 2013 and the 31st of December 2023 at King Fahad Specialist Hospital (KFSH) in Dammam, Saudi Arabia was performed. 
Results: Over a period of 11 years, a total of 50 patients with acute and chronic leukemia presenting with hyperleukocytosis and clinical manifestations of leukostasis; 32 patients with acute leukemia (AL) and 18 patients with chronic myeloid leukemia (CML); received leukapheresis at our institution. Among the 32 patients with AL who received leukapheresis, 24 patients (75%) had acute myeloid leukemia (AML), 7 patients (21.88%) had acute lymphoblastic leukemia (ALL) and 1 patient (3.13%) had bilineage acute leukemia (BAL). At presentation of their AL: 3 patients (9.38%) had fever, 9 patients (28.13%) had infections, 4 patients (12.5%) had palpable spleen or liver, 6 patients (18.75%) had palpable external lymph nodes, and 9 patients (28.13%) had extramedullary disease (EMD). After receiving induction and consolidation cycles of chemotherapy, 11 patients (34.38%) of AL patients received allogeneic hematopoietic stem cell transplantation (HSCT). At the end of the follow-up, 17 patients (53.1%) with AL were alive while 15 patients (46.9%) were dead. The 8-year overall survival (OS) for all patients with AL subjected to leukapheresis was 47%. The 5 years OS for patients with AL who subsequently received HSCT and those who did not receive allogeneic HSCT were 70% and 40% respectively. The mean white blood cell (WBC) count of CML patients subjected to leukapheresis was 465.5 × 109/L, 11 patients (61.11%) had clear signs of leukostasis, and 8 patients (44.44%) had splenomegaly at presentation. Regarding the disease stage at presentation, 14 CML patients (77.78%) had chronic phase (CP), 2 patients (11.11%) had accelerated phase (AP) and 2 patients (11.11%) had blast phase (BP). Regarding the fate of CML patients at the end of the study were: 15 (83.33%) were alive, 1 (5.56%) dead, and 2 (11.11%) were unknown as they lost follow-up. However, the 10-year OS of patients with CML subjected to leukapheresis was 90%. 
Conclusion: Patients with acute or chronic leukemia presenting with hyperleukocytosis and either ongoing or impending leukostasis should have urgent cytoreductive chemotherapy and leukapheresis to prevent life-threatening complications. Although the outcome of AL patients presenting with leukostasis is generally poor, prompt cytoreductive therapy and leukapheresis, followed by induction chemotherapy and allogeneic HSCT may improve the outcome. Also, urgent cytoreduction including leukapheresis improves the outcome of patients with CML presenting with hyperleukocytosis and leukostasis.

Read Full Article HTML DOI: 10.29328/journal.jhcr.1001028 Cite this Article Read Full Article PDF

Keywords:

Hyperleukocytosis; Leukostasis; Leukapheresis; Acute leukemia; Chronic myeloid leukemia; Hematopoietic stem cell transplantation

References

  1. Dekker SE, Rea D, Cayuela JM, Arnhardt I, Leonard J, Heuser M. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390010. doi: 10.1200/EDBK_390010. PMID: 37311155.
  2. Huerga-Domínguez S, Villar S, Prósper F, Alfonso-Piérola A. Updates on the Management of Acute Myeloid Leukemia. Cancers (Basel). 2022 Sep 29;14(19):4756. doi: 10.3390/cancers14194756. PMID: 36230677; PMCID: PMC9563665.
  3. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Röllig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Löwenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-1377. doi: 10.1182/blood.2022016867. PMID: 35797463.
  4. Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023 Feb 1;108(2):308-320. doi: 10.3324/haematol.2022.280801. PMID: 36722402; PMCID: PMC9890016.
  5. Rabian F, Boissel N. LAL chez l’adulte : apport et limite de la prise en charge pédiatrique [ALL in adult patients: Contribution and limits of pediatric management]. Bull Cancer. 2021 Feb;108(2):187-197. French. doi: 10.1016/j.bulcan.2020.07.008. Epub 2020 Sep 24. PMID: 32981690.
  6. Hoelzer D, Bassan R, Boissel N, Roddie C, Ribera JM, Jerkeman M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia. Ann Oncol. 2024 Jan;35(1):15-28. doi: 10.1016/j.annonc.2023.09.3112. Epub 2023 Oct 11. PMID: 37832649.
  7. Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020 Jun 5;13(1):70. doi: 10.1186/s13045-020-00905-2. PMID: 32503572; PMCID: PMC7275444.
  8. DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014. Epub 2019 Aug 22. PMID: 31446198.
  9. de Oliveira Fernandes Junior I, Arcuri LJ. Myeloablative or reduced-intensity/non-myeloablative hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia in adults older than 40 years old - a secondary analysis of a CIBMTR database. Ann Hematol. 2024 Feb;103(2):603-607. doi: 10.1007/s00277-023-05532-8. Epub 2023 Nov 9. PMID: 37940716.
  10. Pan J. Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia. Blood Cell Ther. 2023 Nov 25;6(4):145-150. doi: 10.31547/bct-2023-028. PMID: 38149027; PMCID: PMC10749733.
  11. Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023 Jan;37(1):5-17. doi: 10.1038/s41375-022-01736-5. Epub 2022 Oct 29. PMID: 36309558.
  12. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6. PMID: 35751859.
  13. Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25. PMID: 28743165; PMCID: PMC5673547.
  14. Seftel MD, Pasic I, Parmar G, Bucher O, Allan DS, Bhella S, Hay KA, Ikuomola O, Musto G, Prica A, Richardson E, Truong TH, Paulson K. Hematopoietic Cell Transplantation Trends and Outcomes in Canada: A Registry-Based Cohort Study. Curr Oncol. 2023 Nov 17;30(11):9953-9967. doi: 10.3390/curroncol30110723. PMID: 37999143; PMCID: PMC10669983.
  15. Kong SG, Jeong S, Lee S, Jeong JY, Kim DJ, Lee HS. Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia. BMC Cancer. 2021 Feb 18;21(1):177. doi: 10.1186/s12885-021-07897-3. PMID: 33602150; PMCID: PMC7891151.
  16. Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, Huang X, Nogueras Gonzalez G, Hwang H, Qi X, Kantarjian H, Ravandi F. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020 Dec 1;6(12):1890-1899. doi: 10.1001/jamaoncol.2020.4600. PMID: 33030517; PMCID: PMC7545346.
  17. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, Wood BL, Kelloff GJ, Jessup JM, Radich JP. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017 Jul 13;3(7):e170580. doi: 10.1001/jamaoncol.2017.0580. Epub 2017 Jul 13. PMID: 28494052; PMCID: PMC5824235.
  18. Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023; 329(9): 745-755. doi: 10.1001/jama.2023.1363.
  19. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015 May 21;125(21):3246-52. doi: 10.1182/blood-2014-10-551507. Epub 2015 Mar 16. PMID: 25778528.
  20. Gong J, Wu B, Guo T, Zhou S, He B, Peng X. Hyperleukocytosis: A report of five cases and review of the literature. Oncol Lett. 2014 Oct;8(4):1825-1827. doi: 10.3892/ol.2014.2326. Epub 2014 Jul 8. PMID: 25202418; PMCID: PMC4156199.
  21. Ali AM, Mirrakhimov AE, Abboud CN, Cashen AF. Leukostasis in adult acute hyperleukocytic leukemia: a clinician's digest. Hematol Oncol. 2016 Jun;34(2):69-78. doi: 10.1002/hon.2292. Epub 2016 Mar 27. PMID: 27018197.
  22. Giammarco S, Chiusolo P, Piccirillo N, Di Giovanni A, Metafuni E, Laurenti L, Sica S, Pagano L. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017 Feb;10(2):147-154. doi: 10.1080/17474086.2017.1270754. Epub 2016 Dec 26. PMID: 27967252.
  23. Kong SG, Seo JH, Jun SE, Lee BK, Lim YT. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood Res. 2014 Mar;49(1):29-35. doi: 10.5045/br.2014.49.1.29. Epub 2014 Mar 24. PMID: 24724064; PMCID: PMC3974953.
  24. Farhan S, Anjum F, Al-Qahtani FS and Al-Anazi KA. Chronic myeloid leukemia presenting with priapism. J Leuk 2015; 3:171. doi: 10.4172/23296917.1000171
  25. Kittivisuit S, Jongthitinon N, Sripornsawan P, Songthawee N, Chavananon S, Limratchapong C, McNeil EB, Chotsampancharoen T. Hyperleukocytosis in Childhood Acute Leukemia: Early Complications and Survival Outcomes. Cancers (Basel). 2023 Jun 6;15(12):3072. doi: 10.3390/cancers15123072. PMID: 37370683; PMCID: PMC10295972.
  26. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments? Cells. 2020 Oct 17;9(10):2310. doi: 10.3390/cells9102310. PMID: 33080779; PMCID: PMC7603052.
  27. Aqui N, O'Doherty U. Leukocytapheresis for the treatment of hyperleukocytosis secondary to acute leukemia. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):457-60. doi: 10.1182/asheducation-2014.1.457. Epub 2014 Nov 18. PMID: 25696894.
  28. Aswanetmanee P, Edriss H, Limsuwat C. Pulmonary leukostasis as a complication of leukemia.Southwest Respir Crit Care Chron. 2015; 3(10): 17-22.doi: 10.12746/swrccc2015.0310.028
  29. Singh H, Prasad BN, Jagdish, Batra A. Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia. J Assoc Physicians India. 2006 May;54:405-7. PMID: 16909741.
  30. Rico-Rodríguez J, Villanueva-Ortiz Á, Santana-Cabrera L, Rodríguez-Pérez H. Pulmonary leukostasis with severe respiratory impairment as a debut of acute myeloid leukemia. Int J Crit Illn Inj Sci. 2015 Apr-Jun;5(2):125-6. doi: 10.4103/2229-5151.158423. PMID: 26157660; PMCID: PMC4477392.
  31. Zhang D, Lin H, Huang L. Repeated small-volume exchange transfusion for hyperleukocytosis in pediatric acute leukemia: A retrospective analysis. Front Pediatr. 2023 Mar 22;11:1155481. doi: 10.3389/fped.2023.1155481. PMID: 37033185; PMCID: PMC10073680.
  32. Haase R, Merkel N, Diwan O, Elsner K, Kramm CM. Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience. Klin Padiatr. 2009 Nov-Dec;221(6):374-8. doi: 10.1055/s-0029-1239533. Epub 2009 Nov 4. PMID: 19890790.
  33. Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and Hyperleukocytosis, Past and Future. Int J Gen Med. 2021 Jul 14;14:3457-3467. doi: 10.2147/IJGM.S321787. PMID: 34285568; PMCID: PMC8286901.
  34. Thapa N, Pham R, Cole C, Meinershagen M, Bowman PW, Ray A. Therapeutic leukocytapheresis in infants and children with leukemia and hyperleukocytosis: A single institution experience. J Clin Apher. 2018 Jun;33(3):316-323. doi: 10.1002/jca.21610. Epub 2017 Nov 29. PMID: 29193219.
  35. Bruserud Ø, Liseth K, Stamnesfet S, Cacic DL, Melve G, Kristoffersen E, Hervig T, Reikvam H. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med. 2013 Dec;23(6):397-406. doi: 10.1111/tme.12067. Epub 2013 Aug 6. PMID: 23919332.
  36. Choi MH, Choe YH, Park Y, Nah H, Kim S, Jeong SH, Kim HO. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018 Jan;58(1):208-216. doi: 10.1111/trf.14329. Epub 2017 Sep 28. PMID: 28960357.
  37. Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014 Apr 14;9(4):e95062. doi: 10.1371/journal.pone.0095062. PMID: 24733550; PMCID: PMC3986260.
  38. Malkan UY, Ozcebe OI. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis. Transfus Apher Sci. 2017 Dec;56(6):880-882. doi: 10.1016/j.transci.2017.11.002. Epub 2017 Nov 8. PMID: 29153308.
  39. Rinaldi I, Sari RM, Tedhy VU, Winston K. Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients - A Dual-Center Retrospective Cohort Study. J Blood Med. 2021 Jul 14;12:623-633. doi: 10.2147/JBM.S312140. PMID: 34290537; PMCID: PMC8286962.
  40. Oberoi S, Lehrnbecher T, Phillips B, Hitzler J, Ethier MC, Beyene J, Sung L. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014 Apr;38(4):460-8. doi: 10.1016/j.leukres.2014.01.004. Epub 2014 Jan 10. PMID: 24472688.
  41. Göçer M, Kurtoğlu E. Effect of prophylactic leukapheresis on early mortality and overall survival in acute leukemia patients with hyperleukocytosis. Ther Apher Dial. 2021 Oct;25(5):697-703. doi: 10.1111/1744-9987.13645. Epub 2021 Apr 7. PMID: 33686785.
  42. Berber I, Kuku I, Erkurt MA, Kaya E, Bag HG, Nizam I, Koroglu M, Ozgul M, Bazna S. Leukapheresis in acute myeloid leukemia patients with hyperleukocytosis: A single center experience. Transfus Apher Sci. 2015 Oct;53(2):185-90. doi: 10.1016/j.transci.2015.03.015. Epub 2015 Mar 18. PMID: 25843763.
  43. Bug G, Anargyrou K, Tonn T, Bialleck H, Seifried E, Hoelzer D, Ottmann OG. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007 Oct;47(10):1843-50. doi: 10.1111/j.1537-2995.2007.01406.x. PMID: 17880610.
  44. Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma. 2017; 58(9): 1-11. doi: 10.1080/10428194.2016.1277386. Epub 2017 Jan 31.
  45. Lee H, Park S, Yoon JH, Cho BS, Kim HJ, Lee S, Kim DW, Chung NG, Cho B, Kim KB, Yoo J, Jekarl DW, Chae H, Lim J, Kim M, Oh EJ, Kim Y. The factors influencing clinical outcomes after leukapheresis in acute leukaemia. Sci Rep. 2021 Mar 19;11(1):6426. doi: 10.1038/s41598-021-85918-8. PMID: 33742034; PMCID: PMC7979875.
  46. Aragona M, Aragona F. Morte inattesa da leucostasi e da tumori leucostatici polmonari nelle leucemie mieloidi acute. Studio su quattro casi [Unexpected death by leukostasis and lung leukostatic tumors in acute myeloid leukemia. Study of four cases]. Minerva Med. 2000 Oct;91(10):229-37. Italian. PMID: 11236388.
  47. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987 Dec 15;60(12):3071-9. doi: 10.1002/1097-0142(19871215)60:12<3071::aid-cncr2820601235>3.0.co;2-y. PMID: 3479232.
  48. Pryds K, Rasmussen LE, Andersen NH. Fatal right-sided heart failure due to leukostasis in a patient with leukemic transformation of myelodysplastic syndrome. Clin Case Rep. 2018 Nov 20;7(1):115-119. doi: 10.1002/ccr3.1929. PMID: 30656022; PMCID: PMC6332819.
  49. Katogiannis K, Ikonomidis I, Panou F, Katsimardos A, Divane A, Tsantes A, Iliodromitis E, Kyriakou E. Leukostasis-related fatal cardiopulmonary arrest as initial chronic myeloid leukemia presentation. J Med Cases. 2018; 9(3): 77-82. doi: https://doi.org/10.14740/ jmc2993w
  50. Day M, Jalli S, Harkness W, Earley T. Leukostasis from CML leading to sudden cardiac death. J Am Coll Cardiol. 2022, 79 (9_Supplement) 2995.doi: 10.1016/S0735-1097(22)03986-9
  51. Takahashi N, Sano H, Mochizuki K, Kobayashi S, Ohara Y, Kikuta A. Intracranial Hemorrhage in a Pediatric Patient with Chronic Myeloid Leukemia in Chronic Phase: A Case Report. Case Rep Oncol. 2021 Mar 22;14(1):525-530. doi: 10.1159/000515011. PMID: 33976629; PMCID: PMC8077513.
  52. Ashraf M, Naseeruddin G, Zahra SG, Sultan KA, Kamboh UA, Manzoor M, Farooq M, Ahmad M, Ashraf N. Intracerebral hemorrhage as the first symptomatic manifestation of chronic myeloid leukemia (chronic phase): A case report and literature review. Surg Neurol Int. 2023 Jan 6;14:5. doi: 10.25259/SNI_897_2022. PMID: 36751457; PMCID: PMC9899481.
  53. Tien FM, Hou HA, Tsai CH, Tang JL, Chen CY, Kuo YY, Li CC, Lin CT, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Tseng MH, Liu MC, Liu CW, Lin LI, Chou WC, Tien HF. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. Eur J Haematol. 2018 Jul;101(1):86-94. doi: 10.1111/ejh.13073. Epub 2018 May 22. PMID: 29624746.
  54. Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. Am J Hematol. 2017 Jul;92(7):653-659. doi: 10.1002/ajh.24737. Epub 2017 May 26. PMID: 28370339.
  55. Feng S, Zhou L, Zhang X, Tang B, Zhu X, Liu H, Sun Z, Zheng C. Impact Of ELN Risk Stratification, Induction Chemotherapy Regimens And Hematopoietic Stem Cell Transplantation On Outcomes In Hyperleukocytic Acute Myeloid Leukemia With Initial White Blood Cell Count More Than 100 × 109/L. Cancer Manag Res. 2019 Nov 8;11:9495-9503. doi: 10.2147/CMAR.S225123. PMID: 31807075; PMCID: PMC6850690.

Figures:

Similar Articles

  • Successful management of disseminated Fusarium infection in a patient with acute myeloid leukemia
    AlShammasi S, AlNujaidi D, Bakhit K, Algarni A and AlAnazi KA* AlShammasi S,AlNujaidi D,Bakhit K,Algarni A,AlAnazi KA*. Successful management of disseminated Fusarium infection in a patient with acute myeloid leukemia. . 2018 doi: 10.29328/journal.jhcr.1001007; 2: 015-020
  • Varicella zoster virus: The potentially useful virus
    Al-Anazi KA* and Al-Jasser AM Al-Anazi KA*,Al-Jasser AM. Varicella zoster virus: The potentially useful virus. . 2019 doi: 10.29328/journal.jhcr.1001009; 3: 011-015
  • Evaluation of the Bone Marrow Aspirate Examination Practice at the University Hospital Andrainjato Fianarantsoa, Madagascar
    Bronislaw Tchestérico Dodoson, Jocia Fenomanana, Manevarivo Eddy Ramaminiaina, Stéphania Niry Manantsoa, Zely Arivelo Randriamanantany, Andriamiadana Luc Rakotovao and Aimée Olivat Rakoto Alson Bronislaw Tchestérico Dodoson, Jocia Fenomanana, Manevarivo Eddy Ramaminiaina, Stéphania Niry Manantsoa, Zely Arivelo Randriamanantany, Andriamiadana Luc Rakotovao, Aimée Olivat Rakoto Alson. Evaluation of the Bone Marrow Aspirate Examination Practice at the University Hospital Andrainjato Fianarantsoa, Madagascar. . 2023 doi: 10.29328/journal.jhcr.1001023; 7: 015-020
  • The Outcome of Patients with Leukemia Presenting with Hyperleukocytosis Requiring Leukapheresis. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia
    Khalid Ahmed Al-Anazi*, Alsaffar WA, Aljishi FK, Kanfer S, Kalogiannidis P, Alenazi W, Alshammasi Z, Albahrani A, Abduljalil O, Mutahar E, Alwakeel AM, Apostolidis I, Darweesh M, Almokhtar N, Abdulbaqi M, Albanyan O, Alshaibani Z, Raslan H and Aldayel A Khalid Ahmed Al-Anazi*, Alsaffar WA, Aljishi FK, Kanfer S, Kalogiannidis P, Alenazi W, Alshammasi Z, Albahrani A, Abduljalil O, Mutahar E, Alwakeel AM, Apostolidis I, Darweesh M, Almokhtar N, Abdulbaqi M, Albanyan O, Alshaibani Z, Raslan H, Aldayel A. The Outcome of Patients with Leukemia Presenting with Hyperleukocytosis Requiring Leukapheresis. The Experience of King Fahad Specialist Hospital in Dammam, Saudi Arabia. . 2024 doi: 10.29328/journal.jhcr.1001028; 8: 008-016
  • Assessment of Redox Patterns at the Transcriptional and Systemic Levels in Newly Diagnosed Acute Leukemia
    Ana Carolina Agüero Aguilera, María Eugenia Mónaco, Sandra Lazarte, Emilse Ledesma Achem, Natalia Sofía Álvarez Asensio, Magdalena María Terán, Blanca Alicia Issé, Marcela Medina and Cecilia Haro* Ana Carolina Agüero Aguilera, María Eugenia Mónaco, Sandra Lazarte, Emilse Ledesma Achem, Natalia Sofía Álvarez Asensio, Magdalena María Terán, Blanca Alicia Issé, Marcela Medina, Cecilia Haro*. Assessment of Redox Patterns at the Transcriptional and Systemic Levels in Newly Diagnosed Acute Leukemia. . 2024 doi: 10.29328/journal.jhcr.1001029; 8: 017-023

Recently Viewed

Read More

Most Viewed

Read More

Help ?